Literature DB >> 20023684

Cytomegalovirus prophylaxis: how long is enough?

Deepali Kumar, Atul Humar.   

Abstract

Mesh：

Year:  2010        PMID： 20023684     DOI： 10.1038/nrneph.2009.207

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  6 in total

1.  Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation.

Authors:  V C Emery; C A Sabin; A V Cope; D Gor; A F Hassan-Walker; P D Griffiths
Journal:  Lancet       Date:  2000-06-10       Impact factor: 79.321

2.  Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.

Authors:  Carlos Paya; Atul Humar; Ed Dominguez; Kenneth Washburn; Emily Blumberg; Barbara Alexander; Richard Freeman; Nigel Heaton; Mark D Pescovitz
Journal:  Am J Transplant       Date:  2004-04       Impact factor: 8.086

3.  Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients.

Authors:  Atul Humar; Tony Mazzulli; George Moussa; Raymund R Razonable; Carlos V Paya; Mark D Pescovitz; Emma Covington; Emma Alecock
Journal:  Am J Transplant       Date:  2005-05       Impact factor: 8.086

4.  Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.

Authors:  D Kumar; S Chernenko; G Moussa; I Cobos; O Manuel; J Preiksaitis; S Venkataraman; A Humar
Journal:  Am J Transplant       Date:  2009-05       Impact factor: 8.086

5.  Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.

Authors:  Guy Boivin; Nathalie Goyette; Christian Gilbert; Noel Roberts; Katherine Macey; Carlos Paya; Mark D Pescovitz; Atul Humar; Ed Dominguez; Kenneth Washburn; Emily Blumberg; Barbara Alexander; Richard Freeman; Nigel Heaton; Emma Covington
Journal:  J Infect Dis       Date:  2004-04-13       Impact factor: 5.226

6.  Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection.

Authors:  Fu L Luan; Linda J Stuckey; Jeong M Park; Daniel Kaul; Diane Cibrik; Akinlolu Ojo
Journal:  J Am Soc Nephrol       Date:  2009-09-17       Impact factor: 10.121
  6 in total
  3 in total

1.  Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.

Authors:  Patrick J Hanley; Donald R Shaffer; Conrad R Y Cruz; Stephanie Ku; Benjamin Tzou; Hao Liu; Gail Demmler-Harrison; Helen E Heslop; Clio M Rooney; Stephen Gottschalk; Catherine M Bollard
Journal:  Cytotherapy       Date:  2011-05-04       Impact factor: 5.414

Review 2.  The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care.

Authors:  Francesco Saglio; Patrick J Hanley; Catherine M Bollard
Journal:  Cytotherapy       Date:  2014-02       Impact factor: 5.414

Review 3.  Cellular immune therapy for viral infections in transplant patients.

Authors:  Rajiv Khanna; Corey Smith
Journal:  Indian J Med Res       Date:  2013-11       Impact factor: 2.375
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.